Merck Animal Health receives USDA approval of canine flu bivalent vaccine
Merck Animal Health announced that the U.S. Department of Agriculture has approved a license for Nobivac Canine Flu Bivalent vaccine - the first vaccine to aid in the control of disease associated with both canine influenza virus H3N2 and canine influenza virus H3N8. CIV H3N2 was identified last year in the United States following multiple outbreaks throughout the country. "Merck Animal Health has a rich history of vaccine development supported by a wealth of expertise, as well as a deep commitment to bringing innovative products to market that truly impact the health and well-being of animals," said KJ Varma, BVSc, Ph.D., senior vice president, R&D, Merck Animal Health. "Our new bivalent canine influenza vaccine will simplify protection against this disease and is a tremendous example of our ongoing pursuit of the science of healthier animals and our dedication to providing veterinarians with new medicines and vaccines to advance optimal pet care."